Compare InMode Ltd (INMD) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
InMode Ltd vs Viatris Inc — how do they compare? InMode Ltd trades at $14.19 (market cap $809.93M), while Viatris Inc trades at $17.62 (market cap $20.03B). The key difference: Viatris Inc is far larger — about 24.7× InMode Ltd's market cap, and Viatris Inc pays a 2.75% dividend while InMode Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold InMode Ltd for 28 Days and Viatris Inc for 57 Days on average.
| INMD | VTRS | |
|---|---|---|
Market Cap | $809.93M | $20.03B |
Volume | 365,490 | 14,109,977 |
Sector | Health | Health |
52-Week High | $16.62 | $18.27 |
52-Week Low | $12.76 | $9.74 |
Typical Hold Time | 28 Days | 57 Days |
Enterprise Value | $313.27M | $32.15B |
Dividend Yield | — | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INMD trades at $14.14, up 0.93% on the day, with bearish technical signals from moving averages but attractive valuation metrics including a P/E of 11.63 and EV/EBITDA of 4.48. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1 2026, while maintaining strong profitability with 76.52% gross margins. Recent developments include the launch of Morpheus8 Cool technology and an unsolicited acquisition offer from Steel Partners at $16.75 per share.
The stock presents value opportunity with solid fundamentals but faces near-term headwinds from cyclical industry softness and management capital allocation concerns. Analyst sentiment is divided with 45% buy ratings versus 55% hold, suggesting cautious optimism amid ongoing strategic review of the acquisition proposal.
Viatris (VTRS) trades at $17.625, up 0.77% with a bullish technical signal. The company shows mixed fundamentals with declining revenue from $16.3B in 2022 to $14.3B in 2025 and negative net income margins, though recent quarters have beaten EPS estimates. Positive cash flow trends and a $0.12 dividend signal financial stability. Analyst consensus is mixed with 38% buy ratings and a $22.17 price target suggesting 26% upside.
The outlook balances operational strength against profitability challenges. Investment appeal lies in value metrics (P/S 1.38), consistent earnings beats, and dividend yield, but risks include sustained negative margins, high debt, and competitive pressures. The stock's re-rating depends on margin improvement and pipeline execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About InMode Ltd
InMode provides innovative medical technologies for minimally invasive surgical procedures. Its platforms use radiofrequency (RF) energy for aesthetic treatments like body contouring and skin tightening.
Read more on INMD →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
